Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.

Autor: Alsheikh A; King Abdulaziz University Hospital, Jeddah, Saudi Arabia.; Dr. Suliman Fakeeh Hospital, Jeddah, Saudi Arabia., Alshehri A; King Fahad Medical City, Riyadh, Saudi Arabia., Alzahrani S; King Fahad Medical City, Riyadh, Saudi Arabia., Jammah AA; King Saud University Medical City, Riyadh, Saudi Arabia.; Alhammadi Hospital, Riyadh, Saudi Arabia., Alqahtani F; Tadawi Medical Center, Abha, Saudi Arabia., Alotaibi M; Alhammadi Hospital, Riyadh, Saudi Arabia.; Dr Suliman Alhabeeb Hospital, Alolya, Riyadh, Saudi Arabia., Aldahash R; Dr Suliman Alhabeeb Hospital, Alolya, Riyadh, Saudi Arabia.; King Abdallah Medical City, National Guard, Riyadh, Saudi Arabia., Alhozali AM; King Abdulaziz University Hospital, Jeddah, Saudi Arabia.; International Medical Center, Jeddah, Saudi Arabia., Alsabaan F; Security Forces Hospital, Riyadh, Saudi Arabia., Almehthel M; King Fahad Medical City, Riyadh, Saudi Arabia., Aljuhani N; East Jeddah Hospital, Jeddah, Saudi Arabia., Aldabeis A; Security Forces Hospital, Riyadh, Saudi Arabia., Alamri M; Southern Armed Forces Hospital, Khamis Mushait, Saudi Arabia., Maghawry W; Alnahda Polyclinic, Jeddah, Saudi Arabia., Alzaman N; Department of Medicine, College of Medicine, Taibah University, Madinah, Saudi Arabia.; Madina Medical Center, Madinah, Saudi Arabia., Alshaikh A; King Abdallah Medical City, National Guard, Jeddah, Saudi Arabia., M Alnozha O; Department of Medicine, College of Medicine, Taibah University, Madinah, Saudi Arabia.; Saudi German Hospital, Madinah, Saudi Arabia., Issak ER; Department of Internal Medicine, Ain Shams University, Cairo, Egypt. dr.emad.r.h.issak@gmail.com., Alsifri S; Alhada Armed Forces Hospital, Taif, Saudi Arabia.
Jazyk: angličtina
Zdroj: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2024 Feb; Vol. 15 (2), pp. 473-485. Date of Electronic Publication: 2023 Dec 19.
DOI: 10.1007/s13300-023-01516-z
Abstrakt: Introduction: This study aimed to assess the safety and effectiveness of semaglutide, administered either by weekly subcutaneous (SC) injection or orally, in real-life practice in Saudi Arabia in individuals with type 2 diabetes mellitus (T2DM).
Methods: A retrospective chart review study was conducted at 18 Saudi Arabia centers. An accredited centralized institutional review board approved the study. Medical records were included for individuals of any age ≥ 18 years with uncontrolled T2DM. The primary outcome measure was the laboratory glycated hemoglobin (HbA1c) level. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after 6 and 12 months of semaglutide initiation.
Results: The analysis of this study included 1223 patients with uncontrolled T2DM (HbA1c > 7%). The mean (SD) baseline HbA1c was 10.02% (1.17). HbA1c was reduced by an average of 3.02% (0.84) and 3.17% (0.84) at 6 and 12 months, respectively. Results of a repeated measure analysis of variance (ANOVA) indicated significant differences in HbA1c (p value < 0.001). HbA1c levels at 6 and 12 months were significantly lower, 7.00% (0.70) and 6.85% (0.69), than at baseline, 10.02% (1.17). About 193 patients (56.4%) of the 295 patients having HbA1c < 9% achieved HbA1c of 5.7% or less. The frequency of hypoglycemia events was 4.60 (1.10) in the 3 months before semaglutide was initiated. The frequency of hypoglycemia events in the last 3 months was 2.30 (0.80) events and 0.80 (0.50) events at 6-month and 12-month follow-up visits, respectively. The percent reduction in body mass index (BMI) was an average of 13.07% (1.53) and 19.89% (4.07) at 6 and 12 months, respectively. Lipid profile and blood pressure were improved at 6 and 12 months.
Conclusion: Semaglutide, administered either by SC injection or orally, provided substantial glycemic and weight-loss benefits in adults with T2DM.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje